Skip to main content
SEER logo

SEER · Seer, Inc.

Track SEER — free
$1.50 -0.07 (-4.46%)
Market Cap
$87.63M
Shares
55.81M
Volume · Nov 16 56.5K Avg daily vol (3M) 215.53K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.57 Open$1.59 Day$1.53–1.59 52W close$1.57–2.33 Avg vol 30d187K Short int81K · 0.1% of shares · 1.0d Short vol37% Last earningsNov 10, 2026 DataDec 2020–Nov 2026 Filing10-Q · Nov 10

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 10
Earnings call
Revenue outlook cut despite third-quarter growth

Seer reported third-quarter revenue of $4.0 million versus $3.1 million, but cut full year 2026 revenue guidance to $13.5 million to $14.5 million from $16 to $18 million amid funding constraints and delayed purchases.

3 source passages
Total revenue for the third quarter of 2026 was $4.0 million, compared with $3.1 million in the second quarter. We are updating our full year 2026 revenue guidance to $13.5 million to $14.5 million from our prior range of $16 to $18 million. Funding constraints in academic and government research have extended sales cycles and delayed the start of some studies. Open the document at this passage
Nov 10
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue falls 20% as nine-month net loss narrows

Seer reported a 20% revenue decline for the nine months ended September 30, 2026, while net loss narrowed to $47.5 million from $57.6 million. Cash, cash equivalents and investments totaled $198.1 million, while operating cash use was $34.5 million.

Read from the MD&A section
5 source passages
Revenue for the nine months ended September 30, 2026 decreased by $2.5 million, or 20%, compared to the same period in 2025. We incurred net losses of $47.5 million and $57.6 million during the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, we had an accumulated deficit of $513.4 million, and cash, cash equivalents, and investments of $198.1 million. During the nine months ended September 30, 2026, cash used in operating activities was $34.5 million, attributable to a net loss of $47.5 million and a net change in our operating assets and liabilities of $2.2 million, partially offset by non-cash charges of $15.1 million. growing our service offering through the Seer Technology Access Center (“STAC”). Open the document at this passage
Nov 10
Current report 8-K
Revenue guidance cut as third-quarter revenue reaches $4.0 million

Seer reported third-quarter revenue of $4.0 million and cut full-year 2026 revenue guidance to $13.5 million to $14.5 million from $16 million to $18 million, citing funding pressure and delayed opportunities.

Financial results
3 source passages
Seer reported third-quarter revenue of $4.0 million, compared with $3.1 million in the second quarter of 2026, and ended the quarter with approximately $198.1 million in cash, cash equivalents and investments. Seer now expects full-year 2026 revenue to be in the range of $13.5 million to $14.5 million, compared with the prior range of $16 million to $18 million. Continued pressure on academic and government funding has extended sales cycles, and several late-stage opportunities are now expected to close later than planned. Open the document at this passage
Oct 29
Current report 8-K
Special Committee rejects acquisition proposals; company remains independent

Seer, Inc.’s Special Committee unanimously rejected two unsolicited acquisition proposals, concluding a sale would undervalue the company, leaving it as an independent public company. The Radoff-JEC Group proposed $2.55 per share in cash plus a contingent value right.

Other events
3 source passages
Seer to Remain an Independent Public Company Following Conclusion of Special Committee Review Process After careful consideration, the Special Committee determined that both of the unsolicited acquisition proposals fail to reflect Seer’s intrinsic value. As such, the Special Committee has unanimously rejected both unsolicited acquisition proposals. On July 28, 2026, Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”) submitted an unsolicited, non-binding proposal to acquire all outstanding shares of Seer’s Class A common stock for $2.55 per share in cash plus a contingent value right. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$14.08M
Trailing 12 months
Net income (TTM)
−$63.47M
Trailing 12 months
Revenue growth YoY
-3.4%
Year over year
Operating margin
-469.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-52.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$29.32M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.3%
Year over year · more shares
Price change (1Y)
-23.0%
Trailing year
Short interest
0.1%
Latest settlement · 1.0 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 10, 2026
Q3 FY26

TL;DR. Revenue increased sequentially to $4.0 million, net loss narrowed, and SEER retained substantial cash and scientific validation of its platform. New pharmaceutical adoption and repeat consumable purchases supported growth, but full-year revenue guidance was reduced to $13.5 million–$14.5 million amid funding-related delays, lower year-over-year revenue, sequential gross-margin pressure, flat consumable pull-through, and negative free cash flow.

Bullish
  • + Third-quarter revenue increased sequentially to $4.0 million from $3.1 million. new
  • + Established customers continued buying consumables, while several new large pharmaceutical customers purchased instruments and consumables. new
  • + Net loss narrowed to $13.7 million from $18.2 million in the prior-year period. new
  • + SEER ended the quarter with approximately $198.1 million in cash, cash equivalents, and investments and believes its capital is sufficient to reach cash flow breakeven. new
  • + Publications, preprints, and reviews describing Proteograph research increased to 116 from 95. new
  • + SEER will remain an independent public company, and ITC investigative staff recommended granting the full exclusion and cease-and-desist orders requested in its Nanomics investigation. new
Bearish
  • − Full-year 2026 revenue guidance was reduced to $13.5 million–$14.5 million from $16 million–$18 million. new
  • − Revenue decreased 3% from the prior-year period, to $4.0 million from $4.1 million. new
  • − Gross margin declined 130 basis points sequentially to 47%. new
  • − Funding constraints and customer uncertainty over SEER's future extended revenue-conversion timelines, delaying several late-stage opportunities. new
  • − Free cash flow was approximately negative $34.8 million for the first nine months of 2026.
  • − Consumable pull-through was relatively flat sequentially and purchasing remained project-driven, with gaps between customer reorders. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −18%
below
Price vs 50-day avg −19%
below
RSI (14) 28
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −23%
trailing
6-month return −16%
trailing
YTD return −14%
this year
Relative strength −17%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
48 of 59 funds reported for Sep 30 · net +295.6K sh shares · +10 new
Insider flow Distributing
Net -$14.8K over 90 days · 100% sells
Short interest Falling
0.15% of shares out · ▼ -14.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
59 holders — near 3-yr low, contrarian setup
Squeeze score 28
low risk · 0–100
Fundamentals
Excellent
Revenue growth +17%
Y/Y
Gross margin 51%
expanding
EPS growth +9%
Y/Y
Free cash flow $-46.2M
Buyback $25.0M
remaining
Balance sheet $47.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 56%
annualized · 1-yr
Max drawdown −33%
past year
ATR 6.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 3 of last 4
Latest guidance · from the Earnings Call filed Nov 10, 2026
full year 2026
Revenue Lowered $13.5M – $14.5M
Aug 11, 2026 $16M – $18M changed to Nov 10, 2026 $13.5M – $14.5M
prior FY $16.58M midpoint −15.6% Y/Y
long-term
Gross margins 70% – 75%
Guided vs delivered · last 4 settled
Revenue full year 2025
guided $17M – $18M
$16.58M Miss −5.3%
Revenue full year 2024
guided $13M – $15M
$14.17M In line
Revenue fiscal year 2023
guided $16M – $18M
$16.66M In line
Revenue full year 2022
guided $14M – $16M
$15.49M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−18% Bearish
Price vs 50-day avg
−19% Bearish
RSI (14)
28 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
48 of 59 funds reported for Sep 30 · net +295.6K sh shares · +10 new
Insider flow Distributing
Net -$14.8K over 90 days · 100% sells
Short interest Falling
0.15% of shares out · ▼ -14.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
59 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $2 Now $2 · 0% Range high $2
vs 200-day avg -18% vs 50-day avg -19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SEER
Seer, Inc.
this stock
$87.63M -14.2% +17.0% — 0.1%
VRTX
Vertex Pharmaceuticals Inc
$136.56B +18.8% +46.2% 34.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$98.84B +23.8% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
$90.38B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
$66.05B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
65
% held
37.3%
Reported
48 of 59
Top holder
SOFTBANK GROUP CORP.
Held Float
View
Held by Funds
Fund positions
36
View
Short & Settlement
Short Interest Falling
Shares short
81.1K
Days to cover
1.0d
Change
-13.3K sh
View
Short Volume
Short vol %
37%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
636
Value
$1.2K
As of
Sep 11, 2026
View
Off-Exchange
Off-exchange %
53.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$14.8K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$16.6M
Net income (FY)
$-73.6M
EPS diluted
$-1.35
View
Buybacks
Authorized
$50.0M
Remaining
$25.0M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 10, 2026
This year
47

Seer reported third-quarter revenue of $4.0 million and cut full-year 2026 revenue guidance to $13.5 million to $14.5 million from $16 million to $18 million, citing funding pressure and delayed opportunities.

View
Proposed Sales
Value
$23.3K
Shares
10.7K
Filed
Jul 8, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
Seer Reports Third Quarter 2026 F…
Published
Nov 10, 2026
View

Performance

5D 20D 120D MTD YTD
SEER -3.7% -22.7% -16.0% -6.6% -14.2%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -6.3% -21.5% -16.5% -6.4% -24.8%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$50.00M
Spent (derived)
$25.00M
Remaining
$25.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1726445 CUSIP 81578P106 13F (30d) 57 filings 44 filers Visit website Investor relations